Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 2/2016

01-04-2016 | Original Paper

Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study

Authors: Mehmet Bugrahan Duz, Omer Faruk Karatas, Esra Guzel, Nesrettin Fatih Turgut, Mehmet Yilmaz, Chad J. Creighton, Mustafa Ozen

Published in: Cellular Oncology | Issue 2/2016

Login to get access

Abstract

Background

Of all human oral carcinomas, 41 % are localized to the tongue. Despite considerable improvements in both diagnosis and treatment, tongue squamous cell carcinoma (TSCC) has remained one of the most lethal types of cancer. Here, we aimed at identifying a salivary microRNA (miRNA) expression signature specific for TSCC patients.

Methods

To identify putative diagnostic biomarkers, we compared the miRNA expression profiles of saliva samples from three TSCC patients and four healthy control individuals using an Agilent miRNA microarray platform (V19). Three of the differentially expressed miRNAs identified were selected for further validation using quantitative reverse-transcription PCR (qRT-PCR) in saliva samples from 25 TSCC patients and 25 healthy control individuals.

Results

Through microarray-based expression profiling, we found that 419 miRNAs were deregulated in the saliva samples from the TSCC patients compared to those from the healthy control individuals tested. Subsequent qRT-PCR analysis revealed that the expression level of miR-139-5p was significantly reduced in the TSCC validation samples compared to the controls. Further analysis of post-operative saliva samples derived from TSCC patients revealed that the miR-139-5p expression levels had turned back to normal again. In addition, we found that miR-139-5p exhibited enough power to discriminate pre-operative TSCC patients from both normal individuals (AUC: 0.805) and post-operative TSCC patients (AUC: 0.713), thereby underscoring its diagnostic potential.

Conclusions

From our results we conclude that saliva can be used as a feasible source for routine TSCC diagnostics and that miR-139-5p may serve as a potential biomarker for early TSCC detection.
Appendix
Available only for authorised users
Literature
1.
J.N. Myers, T. Elkins, D. Roberts, R.M. Byers, Squamous cell carcinoma of the tongue in young adults: increasing incidence and factors that predict treatment outcomes. Otolaryngol. Head Neck Surg. 122, 44–51 (2000)CrossRefPubMed
2.
I.P. Ribeiro, F. Marques, F. Caramelo, J. Pereira, M. Patrício, H. Prazeres, J. Ferrão, M.J. Julião, M. Castelo-Branco, J.B. de Melo, I.P. Baptista, I.M. Carreira, Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management. Cell Oncol. 37, 29–39 (2014)CrossRef
3.
T. Nakaoka, A. Ota, T. Ono, S. Karnan, H. Konishi, A. Furuhashi, Y. Ohmura, Y. Yamada, Y. Hosokawa, Y. Kazaoka, Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell Oncol. 37, 119–129 (2014)CrossRef
4.
R.S. Patel, J.R. Clark, R. Dirven, R. Wyten, K. Gao, C.J. O'Brien, Prognostic factors in the surgical treatment of patients with oral carcinoma. ANZ J. Surg. 79, 19–22 (2009)CrossRefPubMed
5.
S. Müller, Y. Pan, R. Li, A.C. Chi, Changing trends in oral squamous cell carcinoma with particular reference to young patients: 1971–2006. The Emory University experience. Head Neck Pathol. 2, 60–66 (2008)CrossRefPubMedPubMedCentral
6.
A.R. Fakih, R.S. Rao, A.M. Borges, A.R. Patel, Elective versus therapeutic neck dissection in early carcinoma of the oral tongue. Am. J. Surg. 158, 309–313 (1989)CrossRefPubMed
7.
K. Rusthoven, A. Ballonoff, D. Raben, C. Chen, Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer 112, 345–351 (2008)CrossRefPubMed
8.
D. Sidransky, Nucleic acid-based methods for the detection of cancer. Science 278, 1054–1059 (1997)CrossRefPubMed
9.
E. Guzel, O.F. Karatas, A. Semercioz, S. Ekici, S. Aykan, S. Yentur, C.J. Creighton, M. Ittmann, M. Ozen, Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. Int. J. Cancer 136, 875–879 (2015)CrossRefPubMed
10.
J. Hoffmann, A. Munz, M. Krimmel, G. Alfter, Intraoperative and postoperative kinetics of serum tumor markers in patients with oral carcinoma. J. Oral Maxillofac. Surg. 56, 1390–1393 (1998)CrossRefPubMed
11.
M. Krimmel, J. Hoffmann, C. Krimmel, C.P. Cornelius, N. Schwenzer, Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. J. Craniomaxillofac. Surg. 26, 243–248 (1998)CrossRefPubMed
12.
W.R. Kuo, K.W. Lee, K.Y. Ho, S.M. Tsai, F.Y. Chiang, K.H. Juan, Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck. Kaohsiung J. Med. Sci. 15, 152–158 (1999)PubMed
13.
A. Korostoff, L. Reder, R. Masood, U.K. Sinha, The role of salivary cytokine biomarkers in tongue cancer invasion and mortality. Oral Oncol. 47, 282–287 (2011)CrossRefPubMed
14.
Y. Ogawa, Y. Taketomi, M. Murakami, M. Tsujimoto, R. Yanoshita, Small RNA transcriptomes of two types of exosomes in human whole saliva determined by next generation sequencing. Biol. Pharm. Bull. 36, 66–75 (2013)CrossRefPubMed
15.
M. Yakob, L. Fuentes, M.B. Wang, E. Abemayor, D.T. Wong, Salivary biomarkers for detection of oral squamous cell carcinoma - current state and recent advances. Curr. Oral Health Rep. 1, 133–141 (2014)CrossRefPubMedPubMedCentral
16.
C. Salazar, R. Nagadia, P. Pandit, J. Cooper-White, N. Banerjee, N. Dimitrova, W.B. Coman, C. Punyadeera, A novel saliva-based microRNA biomarker panel to detect head and neck cancers. Cell Oncol. 37, 331–338 (2014)CrossRef
17.
S. Hu, J. Wang, J. Meijer, S. Ieong, Y. Xie, T. Yu, H. Zhou, S. Henry, A. Vissink, J. Pijpe, C. Kallenberg, D. Elashoff, J.A. Loo, D.T. Wong, Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum. 56, 3588–3600 (2007)CrossRefPubMedPubMedCentral
18.
L. Seugnet, J. Boero, L. Gottschalk, S.P. Duntley, P.J. Shaw, Identification of a biomarker for sleep drive in flies and humans. Proc. Natl. Acad. Sci. U. S. A. 103, 19913–19918 (2006)CrossRefPubMedPubMedCentral
19.
Y. Güven, I. Satman, N. Dinççağ, S. Alptekin, Salivary peroxidase activity in whole saliva of patients with insulin-dependent (type-1) diabetes mellitus. J. Clin. Periodontol. 23, 879–881 (1996)CrossRefPubMed
20.
L.C. Fletcher, K.E. Burke, P.L. Caine, N.L. Rinne, C.A. Braniff, H.R. Davis, K.A. Miles, C. Packer, Diagnosing Alzheimer's disease: are we any nearer to useful biomarker-based, non-invasive tests? GMS Health Technol. Assess. 9, Doc01 (2013)PubMedPubMedCentral
21.
C. Streckfus, L. Bigler, T. Dellinger, X. Dai, A. Kingman, J.T. Thigpen, The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin. Cancer Res. 6, 2363–2370 (2000)PubMed
22.
X.F. Jin, N. Wu, L. Wang, J. Li, Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell. Mol. Neurobiol. 33, 601–613 (2013)CrossRefPubMed
23.
J.A. Weber, D.H. Baxter, S. Zhang, D.Y. Huang, K.H. Huang, M.J. Lee, D.J. Galas, K. Wang, The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733–1741 (2010)CrossRefPubMed
24.
P.M. Voorhoeve, R. Agami, Classifying microRNAs in cancer: the good, the bad and the ugly. Biochim. Biophys. Acta 1775, 274–282 (2007)PubMed
25.
M. Seven, O.F. Karatas, M.B. Duz, M. Ozen, The role of miRNAs in cancer: from pathogenesis to therapeutic implications. Future Oncol. 10, 1027–1048 (2014)CrossRefPubMed
26.
E.J. Omelia, M.L. Uchimoto, G. Williams, Quantitative PCR analysis of blood- and saliva-specific microRNA markers following solid-phase DNA extraction. Anal. Biochem. 435, 120–122 (2013)CrossRefPubMed
27.
Z. Wang, H. Luo, X. Pan, M. Liao, Y. Hou, A model for data analysis of microRNA expression in forensic body fluid identification. Forensic Sci. Int. Genet. 6, 419–423 (2012)CrossRefPubMed
28.
O.F. Karatas, E. Guzel, I. Suer, I.D. Ekici, T. Caskurlu, C.J. Creighton, M. Ittmann, M. Ozen, miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLos ONE 9(6), e98675 (2014)CrossRefPubMedPubMedCentral
29.
C.J. Liu, S.C. Lin, C.C. Yang, H.W. Cheng, K.W. Chang, Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 34, 219–224 (2012)CrossRefPubMed
30.
K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25, 402–408 (2001)CrossRefPubMed
31.
R.M. Nagler, M. Barak, M. Peled, H. Ben-Aryeh, M. Filatov, D. Laufer, Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21–1 and TPS in oral squamous cell carcinoma. Cancer 85, 1018–1025 (1999)CrossRefPubMed
32.
R. Nagler, G. Bahar, T. Shpitzer, R. Feinmesser, Concomitant analysis of salivary tumor markers--a new diagnostic tool for oral cancer. Clin. Cancer Res. 12, 3979–3984 (2006)CrossRefPubMed
33.
S.S. Yilmaz, E. Guzel, O.F. Karatas, M. Yilmaz, C.J. Creighton, M. Ozen, MiR-221 as a pre- and postoperative plasma biomarker for larynx cancer patients. Laryngoscope (2015). doi:10.​1002/​lary.​25332
34.
T. Blondal, S. Jensby Nielsen, A. Baker, D. Andreasen, P. Mouritzen, M. Wrang Teilum, I.K. Dahlsveen, Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59, S1–S6 (2013)CrossRefPubMed
35.
N.J. Park, Y. Li, T. Yu, B.M. Brinkman, D.T. Wong, Characterization of RNA in saliva. Clin. Chem. 52, 988–994 (2006)CrossRefPubMed
36.
S. Hu, Y. Xie, P. Ramachandran, R.R. Ogorzalek Loo, Y. Li, J.A. Loo, D.T. Wong, Large-scale identification of proteins in human salivary proteome by liquid chromatography/mass spectrometry and two-dimensional gel electrophoresis-mass spectrometry. Proteomics 5, 1714–1728 (2005)CrossRefPubMed
37.
Y. Li, X. Zhou, M.A. St John, D.T. Wong, RNA profiling of cell-free saliva using microarray technology. J. Dent. Res. 83, 199–203 (2004)CrossRefPubMed
38.
N.J. Park, H. Zhou, D. Elashoff, B.S. Henson, D.A. Kastratovic, E. Abemayor, D.T. Wong, Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin. Cancer Res. 15, 5473–5477 (2009)CrossRefPubMedPubMedCentral
39.
T.S. Wong, X.B. Liu, B.Y. Wong, R.W. Ng, A.P. Yuen, W.I. Wei, Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin. Cancer Res. 14, 2588–2592 (2008)CrossRefPubMed
40.
X. Liu, Z. Chen, J. Yu, J. Xia, X. Zhou, MicroRNA profiling and head and neck cancer. Comp. Funct. Genomics, 837514 (2009).
41.
K. Krishnan, A.L. Steptoe, H.C. Martin, D.R. Pattabiraman, K. Nones, N. Waddell, M. Mariasegaram, P.T. Simpson, S.R. Lakhani, A. Vlassov, S.M. Grimmond, N. Cloonan, miR-139-5p is a regulator of metastatic pathways in breast cancer. RNA 19, 1767–1780 (2013)CrossRefPubMedPubMedCentral
42.
H.D. Zhang, L.H. Jiang, D.W. Sun, J. Li, J.H. Tang, MiR-139-5p: promising biomarker for cancer. Tumour Biol. 36, 1355–1365 (2015)CrossRefPubMed
43.
J.K. Rane, M. Scaravilli, A. Ylipää, D. Pellacani, V.M. Mann, M.S. Simms, M. Nykter, A.T. Collins, T. Visakorpi, N.J. Maitland, MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur. Urol. 67, 7–10 (2015)CrossRefPubMed
44.
E. van Rooij, A.L. Purcell, A.A. Levin, Developing microRNA therapeutics. Circ. Res. 110, 496–507 (2012)CrossRefPubMed
45.
L. Boldrup, P.J. Coates, G. Laurell, T. Wilms, R. Fahraeus, K. Nylander, Downregulation of miRNA-424: a sign of field cancerisation in clinically normal tongue adjacent to squamous cell carcinoma. Br. J. Cancer 112, 1760–1765 (2015)CrossRefPubMed
Metadata
Title
Identification of miR-139-5p as a saliva biomarker for tongue squamous cell carcinoma: a pilot study
Authors
Mehmet Bugrahan Duz
Omer Faruk Karatas
Esra Guzel
Nesrettin Fatih Turgut
Mehmet Yilmaz
Chad J. Creighton
Mustafa Ozen
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 2/2016
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-015-0259-z

Other articles of this Issue 2/2016

Cellular Oncology 2/2016 Go to the issue

Original Paper

Human IGF1 pro-forms induce breast cancer cell proliferation via the IGF1 receptor

Original Paper

Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation

Original Paper

Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer

Original Paper

PDCD2 and NCoR1 as putative tumor suppressors in gastric gastrointestinal stromal tumors

Review

PSA and beyond: alternative prostate cancer biomarkers

Original Paper

Down-regulation of osteopontin mediates a novel mechanism underlying the cytostatic activity of TGF-β
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits